Pacritinib: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−28%

Mortality (1)−28%

RCTs (1)−28%

Late (1)−28%

00.511.5+

← Pacritinib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Pacritinib COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.10death10/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.1010/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.10death10/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.10death10/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.1010/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.10death10/998/101

Late treatment−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6

All studies−28%1.28 · 0.53–3.1010/998/10128% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.600.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →

c19early.org

October 2026

Pacritinib COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cafardi (DB RCT)−28%1.28 · 0.53–3.10death10/998/101 Cafardi (DB RCT)−28%1.28 · 0.35–4.61death5/994/101 Cafardi (DB RCT)25%0.75 · 0.43–1.32progression17/9923/101 Cafardi (DB RCT)−6%1.06 · 0.66–1.70progression26/9925/101 Cafardi (DB RCT)−17%1.17 · 0.76–1.81no improv.31/9927/101

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Pacritinib
reduces riskPacritinib
increases risk →